KRM Ayurveda
January 21, 2026 – January 23, 2026
| Price | ₹128 - ₹135 |
| GMP Rumors * | ₹20 |
|---|---|
| Lot size | 1000 |
| Issue size | ₹77.49 cr |
| Allotment | Jan 27, 2026 |
| Listing | Jan 29, 2026 |
KRM Ayurveda Lot(s) Distribution
| Category | Lot(s) | Qty | Amount | Reserved |
|---|---|---|---|---|
| INDIVIDUAL | 2 | 2000 | 270000 | 906 |
| sHNI | 3 | 3000 | 405000 | 87 |
| bHNI | 8 | 8000 | 1080000 | 173 |
KRM Ayurveda Reservation
| Category | Shares Offered | % |
|---|---|---|
| Anchor | 1542000 | 26.86% |
| QIB | 1032000 | 17.98% |
| HNI | 780000 | 13.59% |
| INDIVIDUAL | 1812000 | 31.57% |
| Market Maker | 574000 | 10% |
| Total | 5740000 | 100% |
KRM Ayurveda About
IPO Details
| Total Issue Size | 57,40,000 shares (aggregating up to ₹77.49 Cr) |
| Fresh Issue | 57,40,000 shares (aggregating up to ₹77.49 Cr) |
| Face Value | ₹10/- Per Share |
| Issue Type | Bookbuilding IPO |
| Listing At | NSE SME |
| Share Holding Pre Issue | 1,55,20,800 shares |
| Share Holding Post Issue | 2,12,60,800 shares |
| Market Maker's Portion | |
Key Performance Indicators (KPI)
| KPI | Sep-25 | Mar-25 | Mar-24 |
|---|---|---|---|
| ROE | 21.84% | 67.86% | 33.88% |
| ROCE | 21.84% | 43.33% | 20.80% |
| EPS (BASIC) | 5.24 | 8.06 | 2.27 |
| P/E Pre IPO | 17.32 | ||
| P/E Post IPO | 23.73 |
Company Financial (In ₹Crore)
| Period Ended | Sep-25 | Mar-25 | Mar-24 | Mar-23 |
|---|---|---|---|---|
| Assets | 78.12 | 66.79 | 43.91 | 39.48 |
| Total Income | 48.65 | 76.95 | 67.57 | 89.38 |
| Profit After Tax | 8.14 | 12.1 | 3.41 | 7.6 |
| EBITDA | 12.83 | 19.11 | 7.34 | 11.03 |
| NET Worth | 36.13 | 23.88 | 11.78 | 8.37 |
| Reserves and Surplus | 20.61 | 23.73 | 11.63 | 8.22 |
| Total Borrowing | 25.07 | 31.2 | 23.18 | 19.87 |
About Company
Incorporated on 3 September 2019, KRM Ayurveda Ltd operates a network of Ayurvedic hospitals and clinics across India and has expanded overseas through telemedicine consultations and product sales.
Currently runs 6 hospitals and 5 clinics at multiple locations, providing integrated Ayurvedic healthcare services.
Manufactures Ayurvedic medicines, herbal & botanical remedies, supplements, and wellness / skincare-related products.
Service offerings include hospital-based treatments, clinic consultations, teleconsultation services, and KRM-branded Ayurvedic products.
As of August 31, 2025, the company employs 429 staff across medical, operational, and administrative departments.
IPO proceeds will be utilised for telemedicine facility development (₹13.67 cr), CRM & IT infrastructure (₹1.42 cr), human resources (₹5.44 cr), loan repayment (₹12.50 cr), working capital (₹18.00 cr), and general corporate purposes.
Strength
Qualified Ayurvedic professionals – Skilled physicians and certified therapists ensure consistent treatment quality.
GMP-certified centralized manufacturing – Ensures purity, safety, and efficacy of Ayurvedic medicines.
Trusted brand with repeat clientele – Strong patient loyalty supports recurring revenue and brand equity.
Weakness
Non-ownership of premises – Hospitals and offices are on leased properties; forced relocation could disrupt operations.
Employee attrition risk – Higher attrition among frontline and technical staff may impact service quality and scalability.
Geographical revenue concentration – Majority revenue derived from top two states exposes the company to regional risks.
KRM Ayurveda Lead Manager(s)
KRM Ayurveda Address
Address
A-16
G T Karnal road
North West Delhi, New Delhi, 110033
+91- 9289101700
E-mail: compliance@krmayurveda.com
Website: https://www.krmayurvedaindia.com/